Using these manufacturing modifications and optimized HPC mobilization, in the phase C, 36 SCD patients were treated with a single autologous infusion of CD34+ cells transduced with Lenti-Globin leading to an increase in total hemoglobin levels from 8.5 g per deciliter at baseline to 11g or more from 6 months through 36 months after infusion; HbAT87Q mean levels were 5.2 g/dL and contributed at least 40% of total hemoglobin, with a distribution across over a mean of 85 ± 8% of RBC; VCN was 1.5 copy/cell [33]. This evidence concerns the gene CD34 and Schnyder corneal dystrophy.